Show simple item record

dc.contributor.authorCrawley, C R
dc.contributor.authorForan, J M
dc.contributor.authorGupta, R K
dc.contributor.authorRohatiner, A Z
dc.contributor.authorSummers, K
dc.contributor.authorMatthews, J
dc.contributor.authorMicallef, I N
dc.contributor.authorRadford, John A
dc.contributor.authorJohnson, Stephen A
dc.contributor.authorJohnson, Peter W
dc.contributor.authorSweetenham, J W
dc.contributor.authorLister, T Andrew
dc.date.accessioned2009-11-19T10:07:21Z
dc.date.available2009-11-19T10:07:21Z
dc.date.issued2000-07
dc.identifier.citationA phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. 2000, 11 (7):861-5 Ann. Oncol.en
dc.identifier.issn0923-7534
dc.identifier.pmid10997815
dc.identifier.urihttp://hdl.handle.net/10541/86440
dc.description.abstractBACKGROUND: 'Molecular response' is being investigated as a therapeutic goal in follicular lymphoma (FL). High response rates in FL with the fludarabine combination 'FMD' have been associated with 'molecular remission'. A phase II study of FMD in FL was therefore conducted. PATIENTS AND METHODS: Fifty-four patients, ten of whom were newly diagnosed received FMD. Forty-four percent of the previously treated patients had 'chemoresistant' disease. Treatment comprised: fludarabine 25 mg/m2 days 1-3, mitoxantrone 10 mg/m2 day 1, and dexamethasone 20 mg days 1-5. Blood/bone marrow was collected for quantitation of t(14;18) by 'real-time' PCR. RESULTS: The overall response rate was 37 of 54 (69%), complete responses being seen in 11 patients (20%), with no difference between newly diagnosed and the previously treated patients. However, the response rate in 'chemosensitive' relapse was 84% compared to 44% in patients in whom the last prior regimen had failed. Molecular responses were seen in 17 of 25 and PCR negativity in 8 of 25, although molecular and clinical responses did not always correlate. Toxicity was moderate, 19 patients required admission. However, in 6 of 12 patients, subsequent G-CSF mobilised stem cell harvests failed. CONCLUSIONS: FMD was well tolerated but with a lower than expected response rate. Molecular responses were seen in the majority of responding patients however, 'molecular remission' was rare.
dc.language.isoenen
dc.subjectCancer DNAen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshDNA, Neoplasm
dc.subject.meshDexamethasone
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLymphoma, Follicular
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshMitoxantrone
dc.subject.meshPolymerase Chain Reaction
dc.subject.meshRecurrence
dc.subject.meshTreatment Outcome
dc.subject.meshVidarabine
dc.titleA phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, St. Bartholomew's Hospital, London, UK.en
dc.identifier.journalAnnals of Oncologyen
html.description.abstractBACKGROUND: 'Molecular response' is being investigated as a therapeutic goal in follicular lymphoma (FL). High response rates in FL with the fludarabine combination 'FMD' have been associated with 'molecular remission'. A phase II study of FMD in FL was therefore conducted. PATIENTS AND METHODS: Fifty-four patients, ten of whom were newly diagnosed received FMD. Forty-four percent of the previously treated patients had 'chemoresistant' disease. Treatment comprised: fludarabine 25 mg/m2 days 1-3, mitoxantrone 10 mg/m2 day 1, and dexamethasone 20 mg days 1-5. Blood/bone marrow was collected for quantitation of t(14;18) by 'real-time' PCR. RESULTS: The overall response rate was 37 of 54 (69%), complete responses being seen in 11 patients (20%), with no difference between newly diagnosed and the previously treated patients. However, the response rate in 'chemosensitive' relapse was 84% compared to 44% in patients in whom the last prior regimen had failed. Molecular responses were seen in 17 of 25 and PCR negativity in 8 of 25, although molecular and clinical responses did not always correlate. Toxicity was moderate, 19 patients required admission. However, in 6 of 12 patients, subsequent G-CSF mobilised stem cell harvests failed. CONCLUSIONS: FMD was well tolerated but with a lower than expected response rate. Molecular responses were seen in the majority of responding patients however, 'molecular remission' was rare.


This item appears in the following Collection(s)

Show simple item record